Last updated: August 20, 2026

NewsWK — Florida healthcare providers and medical researchers can now submit applications for $70 million in state cancer innovation funding, part of an ongoing state initiative aimed at advancing diagnostics, treatments, and clinical therapies across the state.

The latest funding cycle was announced during a briefing in Orlando, where state officials highlighted ongoing investments into competitive grants and specialized research initiatives. Since 2019, Florida has directed more than $1.4 billion toward cancer research and patient care initiatives, reflecting an increase of more than 175% in dedicated cancer program funding over that period.

For the 2026–2027 fiscal year alone, Florida has allocated nearly $228 million to cancer research and innovation initiatives.

The state’s primary institutional framework, the $127.5 million Casey DeSantis Cancer Research Program, provides targeted financial backing to facilities designated by the National Cancer Institute (NCI). Participating institutions include the University of Florida Health Cancer Center, Moffitt Cancer Center in Tampa, the Sylvester Comprehensive Cancer Center in Miami, and the Mayo Clinic Comprehensive Cancer Center in Jacksonville. The program, originally enacted in 2014, was expanded and renamed following the First Lady’s breast cancer diagnosis in 2021 and subsequent recovery.

In addition to primary institutional funding, state lawmakers authorized dedicated cancer innovation grants and established a specialized pediatric cancer research incubator, allowing a broader spectrum of medical entities and researchers to compete for targeted state dollars.

“These investments give researchers the freedom to ask important questions, explore new ideas, and follow the evidence wherever it leads,” said Florida Department of Health Secretary and State Health Officer Dr. Joseph Ladapo, emphasizing the administration’s commitment to prioritizing biomedical research.

Why it matters here

For families across Northwest Florida—from Escambia and Santa Rosa counties to Pensacola, Milton, Pace, Gulf Breeze, and Cantonment—statewide cancer investments play a critical role in expanding local clinical trial options and improving regional care standards. While primary tertiary cancer institutes are located in Jacksonville, Gainesville, Tampa, and South Florida, the research developed through these state-backed programs feeds directly into clinical practice guidelines utilized by regional hospitals, including Baptist Health Care and Ascension Sacred Heart in Pensacola.

Competitive innovation grants offer medical innovators and research teams the opportunity to pilot new diagnostic technologies and clinical interventions, which can shorten the timeline required for cutting-edge therapies to reach patients in the Panhandle. By expanding funding beyond standard institutional overhead into project-specific innovation grants, local physicians and regional healthcare networks gain broader access to emerging protocols without requiring patients to travel hundreds of miles for standard trial enrollments.

Cancer Impact Across Florida

The state’s continued focus on funding comes as public health projections show substantial oncology demands across the state. According to estimates from the American Cancer Society, the United States will see approximately 2,114,850 new cancer cases in 2026, leading to an estimated 626,140 deaths nationwide.

Florida accounts for the second-highest projected volume of new diagnoses in the country, trailing only California. The society projects that Florida will record 183,100 new cancer cases in 2026, alongside more than 50,000 cancer-related deaths. Among Florida residents, prostate cancer represents the most frequent new diagnosis, with an estimated 26,970 cases, followed closely by breast cancer at 24,700 cases.

With a growing and aging population across Escambia, Santa Rosa, and surrounding counties, state-backed research dollars remain an integral component in addressing regional healthcare capacity and developing targeted interventions for the most prevalent forms of the disease.